Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.

Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart A, Eiermann W, Szakolczai I and 4 more

Show all authors

Palmer M, Schumacher M, Geberth M, Lisboa B

Journal of clinical oncology : official journal of the American Society of Clinical Oncology1 Dec 2002Cited by 214 (Europe PMC)

PMID12488406DOI10.1200/jco.2002.05.042PepBankPUB-12488406

Publisher page PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialEfficacy outcome
In premenopausal women with node-positive breast cancer, the goserelin versus CMF treatment effect interacted with estrogen receptor status (P = .0016).
In plain wordsIn women with breast cancer, the goserelin versus CMF treatment effect differed by estrogen receptor status.
Peptide
Goserelin
Outcome
MixedTreatment interaction with ER status
Study
n: not reported in source
Comparator
cyclophosphamide, methotrexate, and fluorouracil (CMF)
Outcome group
Tumor growth · Cancer
Studied dose
3.6 mg every 28 days · 2 yearsAs given in this study (human).
Source sentences
Summary
A significant interaction between treatment and estrogen receptor (ER) status was found (P =.0016).
1 context sentence(design, population, supporting numbers)
Summary · context
The Zoladex Early Breast Cancer Research Association study assessed the efficacy and tolerability of goserelin (3.6 mg every 28 days for 2 years; n = 817) versus cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy (six 28-day cycles; n = 823)
Report a problemFND-1248840601
02HumanNon-randomized trialEfficacy outcome
In ER-positive premenopausal breast cancer patients, goserelin was equivalent to CMF for disease-free survival (HR 1.01, 95% CI 0.84 to 1.20).
In plain wordsIn ER-positive breast cancer patients, goserelin and CMF had equivalent disease-free survival.
Peptide
Goserelin
Outcome
No significant changeDisease-free survival in ER-positive patients
Study
n: not reported in source
Comparator
cyclophosphamide, methotrexate, and fluorouracil (CMF)
Outcome group
Tumor growth · Cancer
Studied dose
3.6 mg every 28 days · 2 yearsAs given in this study (human).
Measurements
HR
1.01
ER-positive
95% CI
0.84 to 1.2
ER-positive
Source sentences
Summary
In ER-positive patients (approximately 74%), goserelin was equivalent to CMF for disease-free survival (DFS) (hazard ratio [HR], 1.01; 95% confidence interval [CI], 0.84 to 1.20).
1 context sentence(design, population, supporting numbers)
Summary · context
The Zoladex Early Breast Cancer Research Association study assessed the efficacy and tolerability of goserelin (3.6 mg every 28 days for 2 years; n = 817) versus cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy (six 28-day cycles; n = 823)
Report a problemFND-1248840602
03HumanNon-randomized trialEfficacy outcome
In ER-negative premenopausal breast cancer patients, goserelin was inferior to CMF for disease-free survival (HR 1.76, 95% CI 1.27 to 2.44).
In plain wordsIn ER-negative breast cancer patients, disease-free survival was worse with goserelin than with CMF.
Peptide
Goserelin
Outcome
DecreaseDisease-free survival in ER-negative patients
Study
n: not reported in source
Comparator
cyclophosphamide, methotrexate, and fluorouracil (CMF)
Outcome group
Tumor growth · Cancer
Studied dose
3.6 mg every 28 days · 2 yearsAs given in this study (human).
Measurements
HR
1.76
ER-negative
95% CI
1.27 to 2.44
ER-negative
Source sentences
Summary
In ER-negative patients, goserelin was inferior to CMF for DFS (HR, 1.76; 95% CI, 1.27 to 2.44).
1 context sentence(design, population, supporting numbers)
Summary · context
The Zoladex Early Breast Cancer Research Association study assessed the efficacy and tolerability of goserelin (3.6 mg every 28 days for 2 years; n = 817) versus cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy (six 28-day cycles; n = 823)
Report a problemFND-1248840603
04HumanNon-randomized trialSafety outcome
In premenopausal breast cancer patients, amenorrhea by 6 months exceeded 95% with goserelin versus 58.6% with CMF.
In plain wordsIn premenopausal breast cancer patients, amenorrhea was more frequent with goserelin than with CMF by 6 months.
Peptide
Goserelin
Outcome
IncreaseAmenorrhea by 6 months
Study
n: not reported in source
Comparator
cyclophosphamide, methotrexate, and fluorouracil (CMF)
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.6 mg every 28 days · 2 yearsAs given in this study (human).
Measurements
Amenorrhea
> 95%
goserelin
Amenorrhea
58.6%
CMF
Source sentences
Summary
Amenorrhea occurred in more than 95% of goserelin patients by 6 months versus 58.6% of CMF patients.
1 context sentence(design, population, supporting numbers)
Summary · context
The Zoladex Early Breast Cancer Research Association study assessed the efficacy and tolerability of goserelin (3.6 mg every 28 days for 2 years; n = 817) versus cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy (six 28-day cycles; n = 823)
Report a problemFND-1248840604
05HumanNon-randomized trialSafety outcome
In premenopausal breast cancer patients, amenorrhea at 3 years occurred in 22.6% with goserelin versus 76.9% with CMF.
In plain wordsIn premenopausal breast cancer patients, amenorrhea at 3 years was less frequent after goserelin than after CMF.
Peptide
Goserelin
Outcome
DecreaseAmenorrhea at 3 years
Study
n: not reported in source
Comparator
cyclophosphamide, methotrexate, and fluorouracil (CMF)
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.6 mg every 28 days · 2 yearsAs given in this study (human).
Measurements
Amenorrhea
22.6%
goserelin
Amenorrhea
76.9%
CMF
Source sentences
Summary
Menses returned in most goserelin patients after therapy stopped, whereas amenorrhea was generally permanent in CMF patients (22.6% v 76.9% amenorrheic at 3 years).
1 context sentence(design, population, supporting numbers)
Summary · context
The Zoladex Early Breast Cancer Research Association study assessed the efficacy and tolerability of goserelin (3.6 mg every 28 days for 2 years; n = 817) versus cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy (six 28-day cycles; n = 823)
Report a problemFND-1248840605
06HumanNon-randomized trialSafety outcome
In premenopausal breast cancer patients, chemotherapy-related side effects, including nausea/vomiting, alopecia and infection, were lower with goserelin than CMF during CMF treatment.
In plain wordsIn breast cancer patients, chemotherapy-related side effects were lower with goserelin than CMF during CMF treatment.
Peptide
Goserelin
Outcome
DecreaseChemotherapy-related side effects
Study
n: not reported in source
Comparator
cyclophosphamide, methotrexate, and fluorouracil (CMF)
Outcome group
Adverse events · Whole body
Studied dose
3.6 mg every 28 days · 2 yearsAs given in this study (human).
Source sentences
Summary
Chemotherapy-related side effects such as nausea/vomiting, alopecia, and infection were higher with CMF than with goserelin during CMF treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
The Zoladex Early Breast Cancer Research Association study assessed the efficacy and tolerability of goserelin (3.6 mg every 28 days for 2 years; n = 817) versus cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy (six 28-day cycles; n = 823)
Report a problemFND-1248840606
07HumanNon-randomized trialSafety outcome
In premenopausal breast cancer patients, estrogen suppression side effects were initially higher with goserelin, then lower than CMF after goserelin stopped.
In plain wordsIn women with breast cancer, estrogen suppression side effects were initially higher with goserelin, then lower than CMF after treatment stopped.
Peptide
Goserelin
Outcome
MixedEstrogen suppression side effects
Study
n: not reported in source
Comparator
cyclophosphamide, methotrexate, and fluorouracil (CMF)
Outcome group
Adverse events · Endocrine and hormones
Studied dose
3.6 mg every 28 days · 2 yearsAs given in this study (human).
Source sentences
Summary
Side effects related to estrogen suppression were initially higher with goserelin, but when goserelin treatment stopped, reduced to a level below that observed in the CMF group.
1 context sentence(design, population, supporting numbers)
Summary · context
The Zoladex Early Breast Cancer Research Association study assessed the efficacy and tolerability of goserelin (3.6 mg every 28 days for 2 years; n = 817) versus cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy (six 28-day cycles; n = 823)
Report a problemFND-1248840607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.